BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37269349)

  • 1. The Potential Role of
    Demirbugen Oz M; Ozdemir F; Tok KC; Dural E; Kir Y; Ulusoy M; Gumustas M; Baskak B; Suzen HS
    Expert Opin Drug Metab Toxicol; 2023; 19(5):319-327. PubMed ID: 37269349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alcohol intake potentiates clozapine adverse effects associated to CYP1A2*1C in patients with refractory psychosis.
    Ortega-Vázquez A; Mayen-Lobo YG; Dávila-Ortiz de Montellano DJ; Tristán-López L; Aviña-Cervantes CL; Ríos C; López-López M; Monroy-Jaramillo N
    Drug Dev Res; 2021 Aug; 82(5):685-694. PubMed ID: 33336447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine.
    Eiermann B; Engel G; Johansson I; Zanger UM; Bertilsson L
    Br J Clin Pharmacol; 1997 Nov; 44(5):439-46. PubMed ID: 9384460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and genetic influencing factors on clozapine pharmacokinetics in Tunisian schizophrenic patients.
    Ammar H; Chadli Z; Mhalla A; Khouadja S; Hannachi I; Alshaikheid M; Slama A; Ben Fredj N; Ben Fadhel N; Ben Romdhane H; Chaabane A; Boughattas NA; Gaha L; Zarrouk L; Aouam K
    Pharmacogenomics J; 2021 Oct; 21(5):551-558. PubMed ID: 33731885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients.
    Carrillo JA; Herraiz AG; Ramos SI; Benítez J
    J Clin Psychopharmacol; 1998 Aug; 18(4):311-6. PubMed ID: 9690697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of fluvoxamine augmentation and smoking on clozapine serum concentrations.
    Augustin M; Schoretsanitis G; Pfeifer P; Gründer G; Liebe C; Paulzen M
    Schizophr Res; 2019 Aug; 210():143-148. PubMed ID: 31182321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of lemborexant on pharmacokinetics of clozapine: A potential drug-drug interaction mediated by time-dependent inhibition of CYP3A4.
    Watanabe K; Misaka S; Kanno-Nozaki K; Chiyoda T; Suzuki Y; Sato A; Suto T; Kuroda J; Shimomura K; Miura I; Yabe H
    Br J Clin Pharmacol; 2024 Jan; 90(1):354-359. PubMed ID: 37596710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between CYP1A2 polymorphisms and clozapine-induced adverse reactions in patients with schizophrenia.
    Ferrari M; Bolla E; Bortolaso P; Callegari C; Poloni N; Lecchini S; Vender S; Marino F; Cosentino M
    Psychiatry Res; 2012 Dec; 200(2-3):1014-7. PubMed ID: 22901441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contributions of cholinergic receptor muscarinic 1 and CYP1A2 gene variants on the effects of plasma ratio of clozapine/N-desmethylclozapine on working memory in schizophrenia.
    Islam F; Maciukiewicz M; Freeman N; Huang E; Tiwari A; Mulsant BH; Pollock BG; Remington G; Kennedy JL; Müller DJ; Rajji TK
    J Psychopharmacol; 2021 Jan; 35(1):31-39. PubMed ID: 33143542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring the usefulness of plasma level determination and pharmacogenetics for patients treated with clozapine.
    Sangüesa E; Cirujeda C; Concha J; Padilla PP; García CB; Ribate MP
    Per Med; 2022 May; 19(3):181-192. PubMed ID: 35259926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of CYP3A4 inhibition by grapefruit juice and ketoconazole upon clozapine administration in vivo.
    Lane HY; Chiu CC; Kazmi Y; Desai H; Lam YW; Jann MW; Chang WH
    Drug Metabol Drug Interact; 2001; 18(3-4):263-78. PubMed ID: 11791889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variation in the Response of Clozapine Biotransformation Pathways in Human Hepatic Microsomes to CYP1A2- and CYP3A4-selective Inhibitors.
    Murray M; Zhang WV; Edwards RJ
    Basic Clin Pharmacol Toxicol; 2018 Apr; 122(4):388-395. PubMed ID: 29155491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of alcohol intake in the pharmacogenetics of treatment with clozapine.
    Monroy-Jaramillo N; Martínez-Magaña JJ; Pérez-Aldana BE; Ortega-Vázquez A; Montalvo-Ortiz J; López-López M
    Pharmacogenomics; 2022 Apr; 23(6):371-392. PubMed ID: 35311547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of CYP1A2, CYP2C19, and CYP2D6 genotype- and phenoconversion-predicted enzyme activity on clozapine exposure and symptom severity.
    Lesche D; Mostafa S; Everall I; Pantelis C; Bousman CA
    Pharmacogenomics J; 2020 Apr; 20(2):192-201. PubMed ID: 31616047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal effects of clozapine concentration and clozapine to N-desmethylclozapine ratio on cognition: A mediation model.
    Dal Santo F; Jarratt-Barnham I; González-Blanco L; García-Portilla MP; Bobes J; Fernández-Egea E
    Eur Neuropsychopharmacol; 2020 Apr; 33():158-163. PubMed ID: 32057590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia.
    Ozdemir V; Kalow W; Posner P; Collins EJ; Kennedy JL; Tang BK; Albers LJ; Reist C; Roy R; Walkes W; Afra P
    J Clin Psychopharmacol; 2001 Aug; 21(4):398-407. PubMed ID: 11476124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetics of clozapine treatment response and side-effects in schizophrenia: an update.
    Sriretnakumar V; Huang E; Müller DJ
    Expert Opin Drug Metab Toxicol; 2015; 11(11):1709-31. PubMed ID: 26364648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of CYP1A2 and CYP2D6 polymorphisms on drug metabolism and on insulin and lipid elevations and insulin resistance in clozapine-treated patients.
    Melkersson KI; Scordo MG; Gunes A; Dahl ML
    J Clin Psychiatry; 2007 May; 68(5):697-704. PubMed ID: 17503978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-vitro and in-vivo evaluation of the drug-drug interaction between fluvoxamine and clozapine.
    Chang WH; Augustin B; Lane HY; ZumBrunnen T; Liu HC; Kazmi Y; Jann MW
    Psychopharmacology (Berl); 1999 Jul; 145(1):91-8. PubMed ID: 10445377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring clozapine pharmacokinetics in Tunisian schizophrenic patients: A population-based modelling approach investigating the impact of genetic and non-genetic variables.
    Mansour K; Fredj NB; Ammar H; Romdhane HB; Mhalla A; Chaabane A; Chadli Z; Aouam K
    Basic Clin Pharmacol Toxicol; 2024 Jun; 134(6):805-817. PubMed ID: 38599832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.